Details of the Drug-Related molecule(s) Interaction Atlas

SC-51146 Drug Info

141059-52-1; CHEMBL328492; 2H-1-Benzopyran-2-propanoicacid,7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-; ACMC-1C1U2; 7-(3-(2-(Cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid; AC1L52J5; SCHEMBL1890696; CTK4C2448; BDBM50052017; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-p

Cross-matching ID

PubChem CID

196905

CAS Number

CAS 141059-52-1

TTD Drug ID

DMI0QZ3

General Information of Drug (ID: DMI0QZ3)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukotriene B4 receptor 1 (LTB4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LTB4	DME26RS	Human immunodeficiency virus infection	1C62	Phase 2	[2]
Amelubant	DMUMCB9	Pulmonary disease	1B10-1F85	Phase 2	[3]
Biomed 101	DMQ9KZW	Kidney cancer	2C90.0	Phase 1	[4]
LY293111	DM03FHA	Pancreatic cancer	2C10	Discontinued in Phase 2	[5]
SB-201993	DMIF4VJ	Psoriasis vulgaris	EA90	Discontinued in Phase 2	[6]
CI-949	DMN4QSW	Asthma	CA23	Discontinued in Phase 2	[7]
CP-195543	DM1OSUR	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[8]
LTB 019	DM6G0PN	Asthma	CA23	Discontinued in Phase 2	[9]
LY-223982	DMWB7DO	Asthma	CA23	Discontinued in Phase 2	[10]
CP-105696	DM1C4IN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene B4 receptor 1 (LTB4R)	TTN53ZF	LT4R1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994).
2	LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47.
3	Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63.
4	Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.
5	The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096.
6	(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41.
7	Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8.
8	The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases. Curr Opin Drug Discov Devel. 1999 Nov;2(6):550-6.
9	Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17.
10	Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14.
11	3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).